Roka Bioscience, which develops food safety testing equipment that uses molecular diagnostics, filed on Wednesday with the SEC to raise up to $75 million in an initial public offering. The company targets its equipment, which detects pathogens like Salmonella and E. coli, to food processors, laboratories and government agencies. Roka faces competition from E.I. du Pont de Nemours, 3M and Bio-Rad Laboratories.
The Warren, NJ-based company, which was founded in 2009 and booked $3 million in sales for the 12 months ended March 31, 2014, plans to list on the NASDAQ under the symbol ROKA. BofA Merrill Lynch, Leerink Partners, Cowen & Company and Wedbush PacGrow are the joint bookrunners on the deal. No pricing terms were disclosed.
